These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38073894)

  • 1. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance.
    Wei YM; Wang XJ; Yang XD; Wang CS; Wang LL; Xu XY; Zhao GJ; Li B; Zhu DM; Wu Q; Shen YF
    World J Psychiatry; 2023 Nov; 13(11):937-948. PubMed ID: 38073894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance.
    Wu H; Wang X; Liu X; Sang H; Bo Q; Yang X; Xun Z; Li K; Zhang R; Sun M; Cai D; Deng H; Zhao G; Li J; Liu X; Zhan G; Chen J
    Front Psychiatry; 2022; 13():935769. PubMed ID: 36061293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China.
    Yang Y; Ge H; Wang X; Liu X; Li K; Wang G; Yang X; Deng H; Sun M; Zhang R; Chen J; Cai D; Sang H; Liu X; Zhan G; Zhao G; Li H; Xun Z
    Ann Gen Psychiatry; 2023 Oct; 22(1):37. PubMed ID: 37803378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
    Citrome L; Weiden PJ; McEvoy JP; Correll CU; Cucchiaro J; Hsu J; Loebel A
    CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.
    Bo Q; Wang X; Liu X; Sang H; Xun Z; Zhang R; Yang X; Deng H; Li K; Chen J; Sun M; Zhao G; Liu X; Cai D; Zhan G; Li J; Li H; Wang G
    BMC Psychiatry; 2023 Feb; 23(1):115. PubMed ID: 36810039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study.
    Correll CU; Cucchiaro J; Silva R; Hsu J; Pikalov A; Loebel A
    CNS Spectr; 2016 Oct; 21(5):393-402. PubMed ID: 27048911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study.
    Iyo M; Ishigooka J; Nakamura M; Sakaguchi R; Okamoto K; Mao Y; Tsai J; Fitzgerald A; Takai K; Higuchi T
    Neuropsychiatr Dis Treat; 2021; 17():2683-2695. PubMed ID: 34429604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
    Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.
    Potkin SG; Kimura T; Guarino J
    Ther Adv Psychopharmacol; 2015 Dec; 5(6):322-31. PubMed ID: 26834965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia.
    Feng Y; Shi J; Wang L; Zhang X; Tan Y; Zhao J; Ning Y; Xie S; Liu X; Liu Q; Li K; Wang X; Li L; Xu X; Deng W; Luo X; Wang G
    Psychiatry Clin Neurosci; 2020 Jun; 74(6):336-343. PubMed ID: 31823444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study.
    Correll CU; Findling RL; Tocco M; Pikalov A; Deng L; Goldman R
    CNS Spectr; 2022 Feb; 27(1):118-128. PubMed ID: 33077012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study.
    Miura I; Watabe K; Sakaguchi R; Okamoto K; Maruyama H
    Neuropsychiatr Dis Treat; 2022; 18():2627-2637. PubMed ID: 36387943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis.
    Correll CU; Tocco M; Pikalov A; Hsu J; Goldman R
    Schizophr Res; 2022 Feb; 240():205-213. PubMed ID: 35032906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.
    Higuchi T; Ishigooka J; Iyo M; Hagi K
    Asia Pac Psychiatry; 2020 Mar; 12(1):e12377. PubMed ID: 31837113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
    Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
    Ogasa M; Kimura T; Nakamura M; Guarino J
    Psychopharmacology (Berl); 2013 Feb; 225(3):519-30. PubMed ID: 22903391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.